User banner image
User avatar
  • admin

Posts

Beta Glucan Market Competitive Landscape Report 2025: Key Players Analysis, Company Profiles, Product Developments, Mergers, Strategic Collaborations, and Revenue Forecast Insights

The global beta-glucan market is projected to grow from USD 638.75 million in 2025 to USD 1.14 billion by 2033, achieving a CAGR of 7.60%....

Halal Cosmetics Market Competitive Analysis Report 2025: Key Players, Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts to 2033

The global Halal cosmetics market is forecasted to surge from USD 51.16 billion in 2025 to USD 135.54 billion by 2033, registering a CAGR of...

CBD Skincare Products Market Set to Hit USD 17.67 Billion by 2035, Driven by Rising Demand for Natural and Clean Beauty Solutions | Report by SNS Insider

The CBD Skincare Products Market is expanding as consumers embrace cannabidiol-infused, organic formulations, with the U.S. market growing from USD 0.94 billion in 2025 to...

New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies

“A Statistical Immune Correlates of Protection Model for Predicting Efficacy from Neutralizing Antibody Titers to Establish Immunobridging of Monoclonal Antibodies for Prevention of COVID-19” was...

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025

― Announced positive 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ―...

Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052

WAYNE, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory...

Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026

Results Demonstrate AT-587 To Be Highly Potent In Vitro Against Hepatitis E Virus  Initiation of Phase 1 Clinical Program Anticipated Mid-2026 BOSTON, Feb. 24, 2026...

Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET

WARREN, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful...

Yasam Ayavefe Provides Further Update on Structured Review of Potential Black Penny Dubai Expansion

Yasam Ayavefe confirms the structured evaluation of The Black Penny’s potential Dubai expansion has advanced into a detailed commercial review phase. LONDON – February 24,...

Illumina unveils roadmap of groundbreaking NovaSeq X advancements in data quality, output, speed, and flexibility

40% increase in output to 35 billion reads, up to Q70 quality scores, improved turnaround time, and staggered starts are among the updates to be...